<div>A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with</div><div>Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as</div><div>Induction Therapy and Teclistamab in Combination with Daratumumab and</div><div>Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma</div><div><br /></div>

DSMM XX [GMMG-HD10], MajesTEC-5

Comprehensive Cancer Center Mainfranken

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Plasmozytom (Multiples Myelom)

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

Phase II

Herr Dr. Leo Rasche

Herr Prof. Dr. Martin Kortüm

Herr Dr. Max Bittrich

Medizinische Klinik II, Schwerpunkt Hämatologie/Onkologie

Universitätsklinikum Würzburg

Therapeutisch